NASDAQ:RVPH

Reviva Pharmaceuticals Q4 2024 Earnings Results & Report

Reviva Pharmaceuticals logo
$0.34 +0.05 (+17.96%)
As of 11/20/2026 03:57 PM Eastern

Reviva Pharmaceuticals beat analyst earnings expectations in its Q4 2024 results, released March 31, 2025. The company reported EPS of -$3.00 versus the -$4.40 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
After Market Closes
Conference Call
8:00 AM ET

Reviva Pharmaceuticals EPS Results

Actual EPS
-$3.00
Consensus EPS
-$4.40
Beat/Miss
Beat by +$1.40
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reviva Pharmaceuticals Q4 2024 Earnings FAQ

Reviva Pharmaceuticals (NASDAQ:RVPH) reported earnings of -$3.00 per share for Q4 2024, beating the consensus estimate of -$4.40. The report was announced on Monday, March 31, 2025.

Reviva Pharmaceuticals Earnings Headlines

RVPH: FDA Feedback on New Formulation Imminent
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company focused on developing treatments for disorders involving the central nervous system, respiratory system and inflammation. The company is headquartered in Cupertino, California, and was founded in 2006.

Its lead drug candidate, brilaroxazine (also known as RP5063), is an investigational compound being developed for schizophrenia and other neuropsychiatric conditions. Reviva has also described potential applications for the candidate in respiratory and other disorders. Brilaroxazine is not an approved or marketed medicine.

Reviva’s work centers on research and clinical development of its drug candidates; the company does not currently offer commercial pharmaceutical products.

View Reviva Pharmaceuticals Profile